Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
-
The New Expanded Partnership Will Aim to Support the Dismantling of Systemic Barriers to Equity and Help Strengthen the Health Workforce in
Massachusetts - The Existing Global Partnership Has Provided Screening and Diagnostic Services to Over 8 Million People in Community Settings
Takeda’s work with PIH has focused on strengthening the capacity of communities globally to identify and address health inequities sustainably, leading to improved care at every stage of the patient journey. Takeda has supported PIH in expanding and strengthening its diagnostic and clinical care services to over 8 million people in community settings since the global partnership was initiated.
In this new partnership, Takeda and PIH will focus on achieving the following objectives:
- Establishing additional Health Equity Communities of Practice that will convene leaders to target systemic barriers to equity at the policy level
- Expanding the capacity of local health departments and communities to plan for and deliver programs with a focus on health equity and community inclusion
- Expanding opportunities for community health workers to strengthen the health workforce and bring more community members into the health system
“Our collaboration with Takeda will help advance more equitable community health systems in Massachusetts,” said Kristina St. Cyr Kimani,
In
“Expanding our collaboration with PIH will help improve health outcomes in communities disproportionately affected by health care disparities,” said Dr. Chris Reddick, vice president and head of
To alleviate the growing burden of health care disparities, Takeda is committed to collaborating with community partners to support sustainable health equity solutions that target the root cause of health inequities with the ultimate goal of improving health and creating a brighter future for all.
Learn more about how Takeda is working alongside community partners in the Caring for Tomorrow: 2023 U.S. Community Impact Report: Takeda_CSR_Report_2023.pdf
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in
References:
1J. Gaskin, D., A. LaVeist, T., Turner, A., & Obbin, S. (2023). The Time is Now: The
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611689645/en/
Megan Ostrower
megan.ostrower@takeda.com
+1 772-559-4924
Source: Takeda Pharmaceutical Company Limited